NSRX
HealthcareNasus Pharma Ltd.
$7.57
+$0.02 (+0.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Nasus Pharma Ltd. is a company within the Healthcare sector and Drug Manufacturers - General industry. It has a relatively small scale, with a market capitalization of $68.58M and only 1 employee. The financial health of Nasus Pharma Ltd. shows significant losses, with a net income of -$1,861,000 in the trailing twelve months (TTM). Its margins are all at 0.0%, indicating no profit. The company has negative returns on assets (-106.4%), and its current ratio is low at 0.06. It has cash reserves of $203,000 but debt of $2.56M. The valuation context for Nasus Pharma Ltd. shows a price to book value of -12.92, which may indicate overvaluation or other factors affecting the company's stock price. The P/E and forward P/E ratios are not available, nor is revenue growth or dividend yield.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Nasus Pharma Ltd.
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Visit website →Key Statistics
- Market Cap
- $68.58M
- P/E Ratio
- N/A
- 52-Week High
- $9.99
- 52-Week Low
- $5.90
- Avg Volume
- 4.63K
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- ASE
- Country
- Israel
- Employees
- 1